Sep 8, 2025 07:01AM Biodexa enrolls first patients in Phase 3 trial for FAP treatment

Sep 8, 2025 07:00AM Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Jul 31, 2025 09:30AM Biodexa implements ADR ratio change reducing outstanding shares

Jul 28, 2025 07:00AM Biodexa initiates phase 3 trial for FAP treatment eRapa

Jul 28, 2025 07:00AM How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 15, 2025 04:30PM Biodexa Pharmaceuticals changes ADR ratio to meet nasdaq requirement

Jul 14, 2025 08:31AM Biodexa files CTA in Europe for Phase 3 FAP trial

Jun 18, 2025 07:02AM Biodexa Pharmaceuticals (BDRX) Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025 07:00AM Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 11, 2025 04:30PM Biodexa Pharmaceuticals (BDRX) announces voting results from AGM

May 22, 2025 08:31AM Biodexa Pharmaceuticals (BDRX) Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 12, 2025 08:31AM Biodexa Pharmaceuticals (BDRX) Receives Orphan Drug Designation in Europe for eRapa in FAP

Mar 19, 2025 07:04AM Biodexa Pharmaceuticals (BDRX) on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025 07:00AM With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 10, 2025 08:31AM Biodexa Pharmaceuticals (BDRX) Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 6, 2025 08:31AM Biodexa Pharmaceuticals (BDRX) Appoints Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Feb 12, 2025 07:30AM Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 10, 2025 08:30AM Biodexa Pharmaceuticals (BDRX) Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Jan 22, 2025 08:31AM Biodexa Pharmaceuticals (BDRX) Appoints Gary A. Shangold as Chief Medical Officer

Nov 21, 2024 07:35AM Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 12, 2024 08:49AM Biodexa Pharmaceuticals (BDRX) Regains Nasdaq Compliance

Oct 17, 2024 07:34AM Biodexa Pharmaceuticals' (BDRX) MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Oct 17, 2024 07:30AM Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Oct 15, 2024 04:15PM Biodexa Pharmaceuticals (BDRX) Announces Successful Appeal of Nasdaq Delisting

Oct 4, 2024 08:30AM Biodexa Pharmaceuticals (BDRX) Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110

Sep 19, 2024 04:30PM Biodexa Pharmaceuticals (BDRX) Announces ADR Ratio Change

Sep 16, 2024 08:32AM Biodexa Pharmaceuticals (BDRX) Announces Payment of $3M Final Match Payment Enabling Access to Remainder of $17M CPRIT Grant

Aug 12, 2024 04:40PM Biodexa Pharmaceuticals (BDRX) Files for 10.87M Share Offering by Selling Stockholders

Jul 19, 2024 08:31AM Biodexa Pharmaceuticals (BDRX) Prices $5 Million Registered Direct Offering and Concurrent Private Placement

Jul 11, 2024 08:32AM Biodexa Pharmaceuticals (BDRX) Reports Positive Results Of Phase 2 Trial Of eRapa

Jul 11, 2024 08:30AM Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data